About the Myositis Working Group

Idiopathic inflammatory myopathies (IIM) are rare inflammatory autoimmune diseases, commonly with primary involvement of the skeletal muscle. IIM are multi-system diseases often extending beyond muscle weakness and may involve the lungs, joints, skin, and the gastrointestinal tract.

The aim of the Outcome Measures in Rheumatology (OMERACT) Myositis group is to identify core domains and instruments that reflect the life impact area in IIM, with strong patient participation.

Helene

Helene Alexanderson

Co-Chair

Jin

Jin Park

Co-Chair

chris mecoli

Chris Mecoli

Co-Chair

lisa

Lisa Christopher-Stine

Co-Chair

dana

Dana Direnzo

Fellow

Screenshot 2023-03-20 at 7.15.16 PM

Didem Saygin

Fellow

Screen Shot 2021-02-23 at 9.20.11 AM

Ingrid de Groot

Patient Research Partner

Catherine s

Catherine Sarver

Patient Research Partner

OMERACT Endorsed Core Domain Set for use in Clinical Trials/LOS in Myositis

Screen Shot 2021-02-23 at 9.14.32 AM

Working Group Members:

Screenshot 2023-03-20 at 4.44.49 PM

Interested in joining the working group as a member?

We are excited to invite you to join the OMERACT mailing list! This will ensure you stay updated on our latest news and activities.
In addition to joining our mailing list, we also encourage you to become part of our active Working Groups. Being part of these groups is an opportunity to collaborate with experts in the field, contribute to important discussions, and influence the future direction of rheumatology outcomes research.
We look forward to your valuable contributions and active participation in our community.

Subscribe

* indicates required
Working Groups
Scroll to Top